These observations also raise the possibility that the use of CDK1 and CDK4/6 inhibitors to treat invasive cancer types such as ovarian and bladder cancer might be a viable therapeutic option as they will simultaneously block both cell proliferation and invasive cell migration. This evidence concerns the gene CDK4 and urinary bladder cancer.